Success Metrics

Active Trials
7(88%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_1
2
25%
Ph phase_3
1
13%

Phase Distribution

2

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(8)

Detailed Status

Recruiting6
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 12 (28.6%)
Phase 24 (57.1%)
Phase 31 (14.3%)

Trials by Status

not_yet_recruiting113%
recruiting675%
active_not_recruiting113%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_1

A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

NCT07610564
recruiting

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

NCT07294170
recruitingphase_2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

NCT07284420
recruitingphase_2

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT07673627
recruitingphase_3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT07091630
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07610564Phase 1

A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

Recruiting
NCT07294170

ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

Recruiting
NCT07284420Phase 2

ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod

Recruiting
NCT07673627Phase 2

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

Recruiting
NCT07091630Phase 3

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

Recruiting
NCT07638566Phase 2

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Not Yet Recruiting
NCT07612020Phase 1

A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants

Recruiting
NCT06284954Phase 2

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Active Not Recruiting

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8